abstract |
Provided are an FGFR and a mutation inhibitor thereof, and a preparation method therefor and the use thereof. In particular, provided are an FGFR having a structure of formula (I) and a mutation inhibitor thereof, a preparation method therefor, a pharmaceutical composition containing same, the use thereof as an FGFR and a mutation inhibitor thereof and the use thereof in the preparation of a drug for treating and/or preventing tumors or cancers mediated at least in part by means of an FGFR kinase and for treating a tumor patient having resistance to an FGFR inhibitor, and in particular, the use thereof in the preparation of a drug for treating and/or preventing a tumor patient with mutations at V561, V565, N550, N540, V555, E566, K660 and/or V550 of an FGFR signaling pathway. Each substituent of formula (I) has the same definition as in the description. |